Specifically, disruption of the glycolysis–HNRNPA1-K350 lactylation–PKM2 positive feedback axis represents a promising therapeutic avenue for targeting metabolic vulnerability in BLCA. Here, PKM is linked to bladder transitional cell carcinoma.